In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: Older AML: Ven+HMA vs 7+3Abstract 450: <a href="https://ash.confex.com/ash/2024/webprogram/Paper210320.html">https://ash.confex.com/ash/2024/webprogram/Paper210320.html </a> Abstract 971: <a href="https://ash.confex.com/ash/2024/webprogram/Paper202801.html">https://ash.confex.com/ash/2024/webprogram/Paper202801.html </a> Abstract 969: <a href="https://ash.confex.com/ash/2024/webprogram/Paper199267.html">https://ash.confex.com/ash/2024/webprogram/Paper199267.html </a> Venetoclax resistance mechanisms <a href="https://pubmed.ncbi.nlm.nih.gov/39478230/">https://pubmed.ncbi.nlm.nih.gov/39478230/ </a> FLAG-GO vs FLAG-IDA  <a href="https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine">https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine </a>  CPX-351: Abstract 55: <a href="https://ash.confex.com/ash/2024/webprogram/Paper207094.html">https://ash.confex.com/ash/2024/webprogram/Paper207094.html </a> Abstract 60: <a href="https://ash.confex.com/ash/2024/webprogram/Paper200413.html">https://ash.confex.com/ash/2024/webprogram/Paper200413.html </a> Menin Inhibitors  <a href="https://ash.confex.com/ash/2024/webprogram/Paper194384.html">Abstract 211</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper194384.html">https://ash.confex.com/ash/2024/webprogram/Paper194384.html</a>Abstract <a href="https://ash.confex.com/ash/2024/webprogram/Paper207106.html">212</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper207106.html">https://ash.confex.com/ash/2024/webprogram/Paper207106.html</a>Abstract <a href="https://ash.confex.com/ash/2024/webprogram/Paper194827.html">213</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper194827.html">https://ash.confex.com/ash/2024/webprogram/Paper194827.html</a>Abstracts <a href="https://ash.confex.com/ash/2024/webprogram/Paper198218.html">214</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper198218.html">https://ash.confex.com/ash/2024/webprogram/Paper198218.html</a>Abstract <a href="https://ash.confex.com/ash/2024/webprogram/Paper207072.html">215</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper198218.html">https://ash.confex.com/ash/2024/webprogram/Paper198218.html</a><a href="https://ash.confex.com/ash/2024/webprogram/Paper204375.html">Abstract 216</a> <a href="https://ash.confex.com/ash/2024/webprogram/Paper204375.html">https://ash.confex.com/ash/2024/webprogram/Paper204375.html</a> FLT3 inhibitors Abstract 221: <a href="https://ash.confex.com/ash/2024/webprogram/Paper201595.html">https://ash.confex.com/ash/2024/webprogram/Paper201595.html </a>  MDS Abstract 349: <a href="https://ash.confex.com/ash/2024/webprogram/Paper194510.html">https://ash.confex.com/ash/2024/webprogram/Paper194510.html</a> ATRA in MDS:  <a href="https://ash.confex.com/ash/2024/webprogram/Paper200433.html">https://ash.confex.com/ash/2024/webprogram/Paper200433.html</a>

<description>
 &lt;p&gt;In this episode, we delve into the key clinically relevant abstracts in leukemia and myeloid neoplasms with Dr. Jayastu Senapati from the MD Anderson Cancer Center. Here are the links to the abstracts we discussed: &lt;/p&gt;&lt;p&gt;&lt;strong&gt;Older AML: Ven+HMA vs 7+3&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;Abstract 450: &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper210320.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper210320.html&lt;br&gt;&lt;/a&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;Abstract 971: &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper202801.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper202801.html&lt;br&gt;&lt;/a&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;Abstract 969: &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper199267.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper199267.html&lt;br&gt;&lt;/a&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Venetoclax resistance mechanisms&lt;br&gt;&lt;/strong&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://pubmed.ncbi.nlm.nih.gov/39478230/"&gt;&lt;strong&gt;https://pubmed.ncbi.nlm.nih.gov/39478230/&lt;br&gt;&lt;/strong&gt;&lt;/a&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;FLAG-GO vs FLAG-IDA &lt;br&gt;&lt;/strong&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine"&gt;&lt;strong&gt;https://ashpublications.org/blood/article/144/Supplement%201/1513/532742/Gemtuzumab-Ozogamicin-Added-to-Fludarabine&lt;br&gt;&lt;/strong&gt;&lt;/a&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt; CPX-351:&lt;/strong&gt; &lt;/p&gt;&lt;p&gt;Abstract 55: &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper207094.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper207094.html&lt;br&gt;&lt;/a&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;Abstract 60: &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper200413.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper200413.html&lt;br&gt;&lt;/a&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Menin Inhibitors &lt;br&gt;&lt;/strong&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper194384.html"&gt;Abstract 211&lt;/a&gt; &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper194384.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper194384.html&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Abstract &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper207106.html"&gt;212&lt;/a&gt; &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper207106.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper207106.html&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Abstract &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper194827.html"&gt;213&lt;/a&gt; &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper194827.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper194827.html&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Abstracts &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper198218.html"&gt;214&lt;/a&gt; &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper198218.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper198218.html&lt;/a&gt;&lt;/p&gt;&lt;p&gt;Abstract &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper207072.html"&gt;215&lt;/a&gt; &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper198218.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper198218.html&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper204375.html"&gt;Abstract 216&lt;/a&gt; &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper204375.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper204375.html&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;&lt;strong&gt;FLT3 inhibitors &lt;br&gt;Abstract 221: &lt;/strong&gt;&lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper201595.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper201595.html&lt;br&gt;&lt;/a&gt;&lt;br&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;&lt;strong&gt;MDS&lt;/strong&gt;&lt;/p&gt;&lt;p&gt; Abstract 349: &lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper194510.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper194510.html&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt;&lt;strong&gt;ATRA in MDS: &lt;/strong&gt; &lt;/p&gt;&lt;p&gt;&lt;a href="https://ash.confex.com/ash/2024/webprogram/Paper200433.html"&gt;https://ash.confex.com/ash/2024/webprogram/Paper200433.html&lt;/a&gt; &lt;/p&gt;&lt;p&gt; &lt;/p&gt;
 </description>

Blood Cancer Talks

Episode 57. ASH 2024 Update on Leukemia/Myeloid Neoplasms with Dr. Jayastu Senapati

Episode 57. ASH 2024 Update on Leukemia/Myeloid Neoplasms with Dr. Jayastu Senapati

Description